Clinical Trial Update: Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL [Phase 1, Phase 2]

View source ↗

Summary

The trial evaluating allo GDA-201 natural killer cells for relapsed/refractory B-cell non-Hodgkin lymphoma was terminated, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Allo GDA-201 Natural Killer (NK) Cells (GDA-201 NK cells)

Snippet

Sponsor: Gamida Cell ltd | Conditions: Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-03-25